The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC).
Eleni Efstathiou
Consultant or Advisory Role - Janssen Pharmaceutical
Honoraria - Janssen Pharmaceutical
Research Funding - Astellas Pharma (B); Janssen Pharmaceutical
Other Remuneration - Janssen Pharmaceutical
Mark Anton Titus
No relevant relationships to disclose
Sijin Wen
No relevant relationships to disclose
Aileen SanMiguel
No relevant relationships to disclose
Anh Hoang
No relevant relationships to disclose
Angela De Haas-Amatsaleh
Employment or Leadership Position - Astellas Pharma
Frank Perabo
Employment or Leadership Position - Astellas Pharma
De Phung
Employment or Leadership Position - Astellas Pharma
Patricia Troncoso
Consultant or Advisory Role - Janssen Pharmaceutical
Taoufik Ouatas
Employment or Leadership Position - Astellas Pharma
Christopher Logothetis
Consultant or Advisory Role - Janssen Pharmaceutical
Honoraria - Janssen Pharmaceutical
Research Funding - Astellas Pharma; Janssen Pharmaceutical